AstraZeneca's Pulmicort Posts $65 Mil. In Nine-Month U.S. Sales

AstraZeneca's dry powder inhaled asthma therapy Pulmicort Turbuhaler posted nine-month sales of $65 mil. in the U.S., suggesting that the impact of supply constraints imposed by FDA may be beginning to ease, CEO Tom McKillop reported during an Oct. 28 teleconference on third quarter financial results.